Physician profile
Heather Hammond
NPI 1609429349
$767.10
in general payments reported to CMS, 2019-2025
12 companies · $20.43 in 2025
The $20.43 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $265 · 2022: $346 · 2023: $86.14 · 2024: $49.70 · 2025: $20.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $156.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $180.31 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $178.89 | 2021-2025 | Airsupra, Farxiga |
| Horizon Therapeutics Plc | $115.89 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $98.94 | 2022-2023 | Eliquis |
| Abbvie INC. | $69.57 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $27.50 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.80 | 2021 | |
| Lilly USA, LLC | $17.74 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.53 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.98 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.65 | 2022 | |
| Genentech USA, INC. | $10.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Hammond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.